OmniAb's 2Q26 Jump to $13.4M Revenue Cut Losses-But the $37M Cash Rainy Day Fund Is the Real Test

Revenue and losses improved, but repeatability is still the real question

OmniAb's second quarter repaired the most obvious headline weaknesses. Revenue rose to $13.4 million, up from $3.9 million a year earlier, and the net loss narrowed to $5.9 million from $15.9 million. That does not settle the investing case. It only shifts the debate from survival risk to whether this quarter was a spike or the start of a more durable turn.

Management also raised and narrowed its 2026 outlook, now guiding to revenue of $32 million to $36 million and GAAP operating expenses of $84 million to $88 million. If that updated view rests on repeatable partner demand, investors have a better reason to revalue the business rather than treat Q2 as a one-off rescue.

The caution is straightforward: Q2 revenue was driven primarily by partner milestone revenue, which can improve the income statement without proving a steadier cash stream. Milestone timing can help one quarter and then recede. My read is simple: the stock needs to show that demand is repeatable over the next few quarters before the market assigns a higher multiple.

The business model is becoming easier to see, even if the proof is not complete

OmniAb is leaning into a broader revenue mix

OmniAb is not positioning itself as a one-off discovery shop. It licenses cutting edge discovery research technology, and management also indicated the platform could generate recurring revenue from consumables, software, maintenance, and services. That distinction matters. A business built on technology access, follow-on usage, and services can be sturdier than one that lives from deal to deal.

Q2 strengthened that story because it pointed to broader platform use, not just one narrow win. Management reported 425 active programs, 34 active clinical programs or approved products, and four new clinical entrants in 2026. It also sold two xPloration instruments during Q2, bringing the field total to four. That combination matters because it suggests more partners are engaging with the platform across discovery, clinical advancement, and hardware.

The burden of proof is now tighter

One strong quarter can be dismissed as lucky timing. A larger, advancing portfolio is harder to explain away.

OmniAb also disclosed approximately $340 million in remaining potential milestones tied to clinical-stage programs. That should not be treated as revenue, but it does suggest the funnel is broad enough to support demand beyond a single quarter. The key question is no longer whether demand exists somewhere. It is whether that demand can repeat across programs, instruments, and service layers.

Cash is healthier, but it is also the clearest constraint

Why the balance sheet still matters more than the revenue beat

OmniAb's balance sheet is better than it looked before, but not by much. Management now expects year-end cash of $37 million-$41 million, down from $52 million held at the end of Q2. That is not a distress story. For a proof-and-scale company, though, it is tight enough to matter.

The raised outlook gives OmniAb more runway than before, but it does not remove the constraint. In practical terms, cash is flexibility, and that flexibility is shrinking.

What investors need to see next

This is still not a steady compounder. It is a company trying to turn pipeline activity and a small instrument footprint into something the market values as a true platform.

Watch these signposts: - Whether revenue remains milestone-heavy or becomes more balanced across recurring sources. - Whether the instrument footprint keeps growing beyond the current four in the field. - Whether active programs and clinical progression continue to widen, supporting the case for repeat demand. - Whether cash depletion stays manageable as the company funds growth.

The bullish trigger is simple: OmniAb shows it can convert its pipeline and tool footprint into repeatable commercial activity before cash gets tighter. The invalidation signal is just as clear: another quarter of milestone-led growth, weak evidence of repeat demand, and a cash balance that keeps narrowing the company's margin for error.